In recent days in Toronto, Intronix Technologies announced plans to launch “Myoguide DOC”, a comprehensive software package designed to help clinicians who inject Botulinum Toxins, such as Botox, Dysport and Xeomin to manage their patient’s spasticity and pain.
Myoguide DOC is the first integrated graphics driven patient management system that helps clinicians to document all aspects of their patient’s treatment and outcome tracking, while improving their ability to communicate. Save time, increase productivity, improve communication, and follow patient outcomes, a provided statement explains.
Intronix Technologies Corp. is known for producing the Myoguide™ EMG Guided Injection System, which is designed to help clinicians injecting therapeutic Botox like drugs to manage pain and spasticity. Myoguide works like a Geiger counter generating sound and signal display to help clinicians locate the optimal sites to inject medication to provide relief to their patients.
In short, we’re told that Myoguide DOC electronic medical record software allows clinicians to take control of their patients by documenting exactly what, where why and how, much medication is injected, on anatomically accurate graphics. This provides an “at a glance” view of today’s injections, as well as being able to show previous treatment encounters, colour coded by date.
“We are very fortunate for the opportunity to contribute another element to help clinicians who are treating patients suffering from pain and spasticity. Clinicians using DOC will have an easier time seeing how patients are progressing,” says Dr. Evan Friedman, President of Intronix Technologies.